These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 34919011)

  • 21. Development and application of the adverse outcome pathway framework for understanding and predicting chronic toxicity: I. Challenges and research needs in ecotoxicology.
    Groh KJ; Carvalho RN; Chipman JK; Denslow ND; Halder M; Murphy CA; Roelofs D; Rolaki A; Schirmer K; Watanabe KH
    Chemosphere; 2015 Feb; 120():764-77. PubMed ID: 25439131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of an adverse outcome pathway for radiation-induced microcephaly via expert consultation and machine learning.
    Jaylet T; Quintens R; Benotmane MA; Luukkonen J; Tanaka IB; Ibanez C; Durand C; Sachana M; Azimzadeh O; Adam-Guillermin C; Tollefsen KE; Laurent O; Audouze K; Armant O
    Int J Radiat Biol; 2022; 98(12):1752-1762. PubMed ID: 35947014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Pragmatic Approach to Adverse Outcome Pathway Development and Evaluation.
    Svingen T; Villeneuve DL; Knapen D; Panagiotou EM; Draskau MK; Damdimopoulou P; O'Brien JM
    Toxicol Sci; 2021 Nov; 184(2):183-190. PubMed ID: 34534351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Molecular Pathway and AOP Development Using Gene Network Analysis].
    Tanabe S; Hirose A; Whelan M; Yamada T
    Yakugaku Zasshi; 2020; 140(4):485-489. PubMed ID: 32238629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increasing Scientific Confidence in Adverse Outcome Pathways: Application of Tailored Bradford-Hill Considerations for Evaluating Weight of Evidence.
    Becker RA; Ankley GT; Edwards SW; Kennedy SW; Linkov I; Meek B; Sachana M; Segner H; Van Der Burg B; Villeneuve DL; Watanabe H; Barton-Maclaren TS
    Regul Toxicol Pharmacol; 2015 Aug; 72(3):514-37. PubMed ID: 25863193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of the Adverse Outcome Pathway (AOP): Chronic binding of antagonist to N-methyl-d-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities of children.
    Sachana M; Rolaki A; Bal-Price A
    Toxicol Appl Pharmacol; 2018 Sep; 354():153-175. PubMed ID: 29524501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of an adverse outcome pathway network for breast cancer: a comprehensive representation of the pathogenesis, complexity and diversity of the disease.
    Del'haye GG; Nulmans I; Bouteille SP; Sermon K; Wellekens B; Rombaut M; Vanhaecke T; Vander Heyden Y; De Kock J
    Arch Toxicol; 2022 Nov; 96(11):2881-2897. PubMed ID: 35927586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AOP-DB: A database resource for the exploration of Adverse Outcome Pathways through integrated association networks.
    Pittman ME; Edwards SW; Ives C; Mortensen HM
    Toxicol Appl Pharmacol; 2018 Mar; 343():71-83. PubMed ID: 29454060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse outcome pathways as a tool for the design of testing strategies to support the safety assessment of emerging advanced materials at the nanoscale.
    Halappanavar S; van den Brule S; Nymark P; Gaté L; Seidel C; Valentino S; Zhernovkov V; Høgh Danielsen P; De Vizcaya A; Wolff H; Stöger T; Boyadziev A; Poulsen SS; Sørli JB; Vogel U
    Part Fibre Toxicol; 2020 May; 17(1):16. PubMed ID: 32450889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adverse outcome pathway (AOP) development I: strategies and principles.
    Villeneuve DL; Crump D; Garcia-Reyero N; Hecker M; Hutchinson TH; LaLone CA; Landesmann B; Lettieri T; Munn S; Nepelska M; Ottinger MA; Vergauwen L; Whelan M
    Toxicol Sci; 2014 Dec; 142(2):312-20. PubMed ID: 25466378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Towards a systematic use of effect biomarkers in population and occupational biomonitoring.
    Zare Jeddi M; Hopf NB; Viegas S; Price AB; Paini A; van Thriel C; Benfenati E; Ndaw S; Bessems J; Behnisch PA; Leng G; Duca RC; Verhagen H; Cubadda F; Brennan L; Ali I; David A; Mustieles V; Fernandez MF; Louro H; Pasanen-Kase R
    Environ Int; 2021 Jan; 146():106257. PubMed ID: 33395925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How Adverse Outcome Pathways Can Aid the Development and Use of Computational Prediction Models for Regulatory Toxicology.
    Wittwehr C; Aladjov H; Ankley G; Byrne HJ; de Knecht J; Heinzle E; Klambauer G; Landesmann B; Luijten M; MacKay C; Maxwell G; Meek ME; Paini A; Perkins E; Sobanski T; Villeneuve D; Waters KM; Whelan M
    Toxicol Sci; 2017 Feb; 155(2):326-336. PubMed ID: 27994170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Introducing WikiPathways as a Data-Source to Support Adverse Outcome Pathways for Regulatory Risk Assessment of Chemicals and Nanomaterials.
    Martens M; Verbruggen T; Nymark P; Grafström R; Burgoon LD; Aladjov H; Torres Andón F; Evelo CT; Willighagen EL
    Front Genet; 2018; 9():661. PubMed ID: 30622555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigation of a derived adverse outcome pathway (AOP) network for endocrine-mediated perturbations.
    Ravichandran J; Karthikeyan BS; Samal A
    Sci Total Environ; 2022 Jun; 826():154112. PubMed ID: 35219661
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Challenge for Adverse Outcome Pathway (AOP)-based Chemical Safety Assessment].
    Yamada T; Ashikaga T; Kojima H; Hirose A
    Yakugaku Zasshi; 2020; 140(4):481-484. PubMed ID: 32238628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AOP-helpFinder webserver: a tool for comprehensive analysis of the literature to support adverse outcome pathways development.
    Jornod F; Jaylet T; Blaha L; Sarigiannis D; Tamisier L; Audouze K
    Bioinformatics; 2022 Jan; 38(4):1173-1175. PubMed ID: 34718414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AOP-helpFinder 2.0: Integration of an event-event searches module.
    Jaylet T; Coustillet T; Jornod F; Margaritte-Jeannin P; Audouze K
    Environ Int; 2023 Jul; 177():108017. PubMed ID: 37295163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Linking nanomaterial-induced mitochondrial dysfunction to existing adverse outcome pathways for chemicals.
    Murugadoss S; Vinković Vrček I; Schaffert A; Paparella M; Pem B; Sosnowska A; Stępnik M; Martens M; Willighagen EL; Puzyn T; Roxana Cimpan M; Lemaire F; Mertens B; Dusinska M; Fessard V; Hoet PH
    ALTEX; 2024 Jan; 41(1):76-90. PubMed ID: 37606097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse outcome pathway networks II: Network analytics.
    Villeneuve DL; Angrish MM; Fortin MC; Katsiadaki I; Leonard M; Margiotta-Casaluci L; Munn S; O'Brien JM; Pollesch NL; Smith LC; Zhang X; Knapen D
    Environ Toxicol Chem; 2018 Jun; 37(6):1734-1748. PubMed ID: 29492998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Editorial trend: adverse outcome pathway (AOP) and computational strategy - towards new perspectives in ecotoxicology.
    Baudiffier D; Audouze K; Armant O; Frelon S; Charles S; Beaudouin R; Cosio C; Payrastre L; Siaussat D; Burgeot T; Mauffret A; Degli Esposti D; Mougin C; Delaunay D; Coumoul X
    Environ Sci Pollut Res Int; 2024 Jan; 31(5):6587-6596. PubMed ID: 37966636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.